Clinical Quiz: THRIVE-AA1 and Deuruxolitinib for Alopecia Areata

Alopecia areata, an autoimmune disorder characterized by non-scarring hair loss, has long posed significant challenges for patients and clinicians alike.

With a difficult-to-predict disease course and a significant impact on physical and emotional well-being, patients have faced limited treatment options that often failed to address the underlying mechanisms of the condition.

Until recently, the therapeutic landscape for alopecia areata was defined by off-label treatments with inconsistent efficacy and safety profiles. The approval of targeted therapies, namely baricitinib (Olumiant), ritlecitinib (Litfulo), and deuruxolitinib (Leqselvi), marks a transformative shift in care, providing evidence-based options for those with the disease. These approvals also underscore the growing recognition of alopecia areata as a serious medical condition and the importance of advancing precision medicine in dermatology.

In the quiz below, the final in our 3-part series examining the pivotal data used to support these approvals, we examine the July 2024 approval of deuruxolitinib as the third treatment approved for alopecia areata. Approved based on data from 2 multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trials THRIVE-AA1 and THRIVE-AA2, this quiz focuses on the THRIVE-AA1 trial—testing your knowledge study designs, primary endpoints, and significant outcomes that shaped this treatment milestone.

Editor’s note: This quiz was composed with the assistance of artificial intelligence tools.

References:

1. ^{Sun Pharma. U.S. FDA Approves LEQSELVITM (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata. Sun Pharma. July 25, 2024. Accessed January 21, 2025. https://sunpharma.com/wp-content/uploads/2024/07/Sunpharma-LEQSELVI-Approval-Scenario-Press-Release.pdf.}
2. ^{King B, Senna MM, Mesinkovska NA, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024;91(5):880-888. doi:10.1016/j.jaad.2024.06.097.}